Announced
Synopsis
Cardea Bio, a manufacturer of graphene-based biosensors and Nanosens, a manufacturer of biosensors using CRISPR-Chip technology. Financial terms were not disclosed. The closing of the proposed transaction is subject to stockholder approval, definitive documents and customary closing conditions. “We’re excited to become part of Cardea and develop new and innovative uses for our combined technologies. To help realize the potential, we’re calling all genomics innovators to join the Early Access Program to accelerate our research and product development" Kiana Aran, Nanosens Co-Founder,
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.